Fintel reports that on May 26, 2023, EF Hutton reiterated coverage of Apexigen (NASDAQ:APGN) with a Hold recommendation.
Analyst Price Forecast Suggests 787.78% Upside
As of May 11, 2023, the average one-year price target for Apexigen is 4.79. The forecasts range from a low of 1.41 to a high of $8.40. The average price target represents an increase of 787.78% from its latest reported closing price of 0.54.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Apexigen is 0MM. The projected annual non-GAAP EPS is -1.54.
What is the Fund Sentiment?
There are 33 funds or institutions reporting positions in Apexigen. This is an increase of 4 owner(s) or 13.79% in the last quarter. Average portfolio weight of all funds dedicated to APGN is 0.35%, an increase of 143.72%. Total shares owned by institutions increased in the last three months by 6.03% to 3,542K shares. The put/call ratio of APGN is 0.26, indicating a bullish outlook.
What are Other Shareholders Doing?
Decheng Capital Management III holds 1,895K shares representing 7.68% ownership of the company. No change in the last quarter.
Yu Fan holds 402K shares representing 1.63% ownership of the company. No change in the last quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 254K shares representing 1.03% ownership of the company. No change in the last quarter.
Geode Capital Management holds 179K shares representing 0.72% ownership of the company. No change in the last quarter.
Cvi Holdings holds 150K shares representing 0.61% ownership of the company.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
